Mirikizumab-Mrkz

Introduction Overview

Generic Name

mirikizumab-mrkz

Brand Name

Omvoh

Dosage Form

Single-use vial for intravenous infusion (300 mg/15 mL), single-dose prefilled pen for subcutaneous use (100 mg/mL, 200 mg/2 mL), single-dose prefilled syringe for subcutaneous use (100 mg/mL, 200 mg/2 mL)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Omvoh (mirikizumab-mrkz) is a monoclonal antibody administered via intravenous infusion and subcutaneous injection. Following intravenous administration, the drug is directly introduced into systemic circulation, achieving 100% bioavailability immediately. Subcutaneous administration results in slower and incomplete absorption, influenced by lymphatic uptake mechanisms common to large protein molecules. Studies suggest that peak serum concentrations occur several days post subcutaneous injection, with bioavailability estimated at approximately 50-80%. Absorption may be affected by subcutaneous tissue factors such as blood flow, injection site, and local enzymatic degradation.

Distribution:
Mirikizumab exhibits a limited volume of distribution consistent with large monoclonal antibodies, predominantly confined to vascular and interstitial spaces. It distributes primarily within extracellular fluid compartments, with distribution volume approximately equal to plasma volume. The drug does not significantly cross cellular membranes or the blood-brain barrier. Binding affinity to its IL-23 target contributes to tissue localization primarily in inflamed gastrointestinal tissues, relevant in ulcerative colitis and Crohn’s disease. No significant binding to plasma proteins other than its target has been observed.

Metabolism:
As a biologic agent, Omvoh undergoes catabolism via reticuloendothelial system and proteolytic degradation into small peptides and amino acids, similar to endogenous IgG antibodies. These catabolic processes primarily occur in liver, spleen, and endothelial cells. There is no involvement of hepatic cytochrome P450 enzymes, reducing potential for conventional drug-drug metabolic interactions. Clearance mechanisms involve target-mediated drug disposition, where binding to IL-23 may influence degradation rates.

Elimination:
Mirikizumab is eliminated primarily through intracellular catabolism and reticuloendothelial processes rather than renal or hepatic excretion. The half-life of omvoh approximates typical IgG1 monoclonal antibodies, estimated between 3 to 4 weeks, supporting the monthly dosing regimen. Clearance rates can vary with disease state, presence of anti-drug antibodies, and patient-specific factors such as body weight and immune status. There is no active renal excretion or biliary elimination, minimizing concerns regarding renal or hepatic impairment affecting drug elimination.

Dosage Forms

Available Dosage Forms:
Omvoh is available in multiple formulations designed for intravenous and subcutaneous administration:
- Single-dose vial for intravenous infusion: 300 mg/15 mL (20 mg/mL concentration)
- Single-dose prefilled pen for subcutaneous injection: 100 mg/mL and 200 mg/2 mL (100 mg/mL concentration)
- Single-dose prefilled syringe for subcutaneous injection: 100 mg/mL and 200 mg/2 mL (100 mg/mL concentration)

Dosages for Adults and Adolescents:
Omvoh is FDA-approved for use in adults with moderate to severe ulcerative colitis and Crohn's disease. The dosing schedules differ based on indication:
- Ulcerative Colitis:
- Induction: 300 mg intravenous infusion at weeks 0, 4, and 8; each infusion administered over approximately 30 minutes.
- Maintenance: 200 mg subcutaneous injection every 4 weeks starting week 12, delivered as two consecutive 100 mg injections.
- Crohn's Disease:
- Induction: 900 mg intravenous infusion at weeks 0, 4, and 8; each infusion administered over approximately 90 minutes.
- Maintenance: 300 mg subcutaneous injection every 4 weeks starting week 12, administered as two injections - one 100 mg and one 200 mg injection in any order.

Specific Patient Populations:
Omvoh has not been FDA-approved for pediatric use; safety and effectiveness in children remain under investigation. There is limited data on use in elderly patients, pregnant or breastfeeding women; caution is advised in these populations. Dose adjustments are not currently specified for renal or hepatic impairment due to the drug's elimination via proteolytic degradation rather than direct renal or hepatic clearance. Patients with active infections or history of tuberculosis require screening and management prior to initiation to avoid risk of serious infections. The prefilled pen and syringe devices are designed to facilitate self-administration after proper training, with injection sites including abdomen, thigh, or back of upper arm. Injection should avoid areas of bruising or inflammation and alternate sites are recommended to minimize local reactions.

Mechanism Of Action

Omvoh, known generically as mirikizumab-mrkz, operates through targeted inhibition of interleukin-23 (IL-23), a pivotal cytokine in the pathogenesis of chronic inflammatory diseases such as ulcerative colitis and Crohn's disease. IL-23 is secreted primarily by dendritic cells and macrophages and plays a crucial role in the differentiation, expansion, and survival of Th17 cells, which drive inflammatory processes within the gastrointestinal mucosa.

The molecular action of mirikizumab involves high-affinity binding to the p19 subunit of IL-23, thereby selectively neutralizing IL-23 without affecting the closely related cytokine IL-12. This selective inhibition prevents IL-23 from engaging its receptor on T-helper cells and innate lymphoid cells, disrupting downstream signaling pathways including the STAT3 transcription factor activation. Consequently, this reduces the production of pro-inflammatory mediators such as IL-17 and IL-22 that are responsible for sustaining mucosal inflammation and tissue damage.

Clinically, this targeted blockade leads to suppression of the inflammatory cascade characteristic of inflammatory bowel disease, facilitating mucosal healing and symptom improvement. Unlike broader immunosuppressants, Omvoh’s selective disruption of IL-23 signaling aims to minimize widespread immune compromise, reducing the breadth of systemic immunosuppression and potentially limiting infections and other immune-related adverse effects.

Compared to other immunotherapies such as anti-TNF agents or broad Janus kinase inhibitors, omvoh's mechanism is more selective within the cytokine axis, offering an alternative approach that is supported by clinical trials demonstrating efficacy in patients with moderate to severe ulcerative colitis and Crohn's disease who have inadequate response to prior therapies. Ongoing research continues to elucidate its long-term safety and benefits relative to other biologics targeting different immune pathways.

Pharmacological Actions

Selective inhibition of interleukin-23 (IL-23) to modulate immune response.
Suppression of Th17-mediated inflammatory pathways in the gastrointestinal tract.
Reduction of pro-inflammatory cytokines such as IL-17 and IL-22.
Facilitation of mucosal healing in ulcerative colitis and Crohn’s disease.
Minimization of broad immunosuppression by sparing IL-12 pathways.
Immunomodulation leading to decreased intestinal inflammation and symptom improvement.
Targeted cytokine blockade reducing recruitment and activation of inflammatory cells.
Inhibition of signal transduction via the STAT3 pathway in immune cells.
Limited systemic immune disruption compared to pan-immunosuppressive agents.
Potential to reduce corticosteroid dependence in IBD patients.
Improvement of patient quality of life by controlling flare-ups of inflammatory bowel disease.
Favorable safety profile with a lower incidence of some adverse immune effects.
Used as both induction and maintenance therapy in chronic intestinal inflammation.

Therapeutic Or Clinical Uses

Treatment of moderate to severe ulcerative colitis in adults.
Management of moderately to severely active Crohn’s disease in adults.
Induction therapy to achieve remission in inflammatory bowel diseases.
Maintenance therapy to sustain remission in ulcerative colitis and Crohn’s disease.
Alternative for patients refractory or intolerant to anti-TNF therapies.
Biologic treatment option for patients with inadequate response to conventional immunosuppressants.
Potential to reduce corticosteroid usage in IBD management.
Improvement of intestinal mucosal healing and symptom control.
Off-label exploratory use in other IL-23-mediated autoimmune conditions under investigation.
Treatment in patients who require targeted cytokine modulation with fewer systemic effects.
Use in patients with active inflammation despite prior biologic treatment.
Part of combination therapy strategies to optimize inflammatory bowel disease control.
Option for patients unable to tolerate other biologic agents due to safety concerns.
Long-term use for disease control as monitored by clinical and endoscopic assessments.
Therapeutic intervention aimed at limiting disease progression and complications.

Side Or Adverse Effects

Upper respiratory tract infections including nasopharyngitis and sinusitis.
Joint pain (arthralgia) reported during therapy.
Injection site reactions: redness, pain, swelling at the injection site.
Skin rash and dermatologic hypersensitivity reactions.
Headache of varying intensity reported by patients.
Herpes viral infections, including herpes zoster and simplex episodes.
Serious allergic reactions, including anaphylaxis and infusion-related hypersensitivity.
Increased susceptibility to bacterial, viral, fungal, and opportunistic infections.
Potential drug-induced liver injury evidenced by elevated liver enzymes and bilirubin.
Signs of infections such as fever, chills, flu-like symptoms, cough, and weight loss.
Gastrointestinal symptoms including diarrhea and abdominal pain during infections.
Possible symptoms of liver dysfunction such as jaundice, fatigue, nausea, and vomiting.
Sweating, hives, severe itching, and widespread redness during hypersensitivity events.
Rare but serious infusion reactions including tachycardia, breathing difficulties, and swelling.
Local injection site discomfort that typically resolves without intervention.

Precautions

Do not initiate treatment in patients with active or untreated infections.
Screen for latent tuberculosis prior to starting therapy; treat latent or active TB accordingly.
Monitor liver function tests regularly before and during treatment to detect hepatotoxicity.
Avoid live vaccines before, during, and after treatment until immune function recovers.
Use caution in patients with history of serious allergic or hypersensitivity reactions.
Inform healthcare providers about all current medications to assess infection risk.
Avoid injections in areas of skin that are bruised, tender, red, or hardened.
Use effective contraception during treatment due to unknown fetal risk.
Breastfeeding decisions should consider potential risks due to unknown secretion into milk.
Discontinue therapy if serious infections develop and withhold until resolution.
Careful patient education on recognizing signs of infection and adverse reactions is mandatory.
Consider patient’s vaccination status and update immunizations prior to starting therapy.
Adjust monitoring frequency based on underlying conditions, particularly hepatic disease.
Ensure patients are trained in safe handling and administration techniques for self-injection.
Avoid concomitant use with other immunosuppressive biologics without medical supervision.

Warnings

Risk of serious hypersensitivity reactions including anaphylaxis; emergency treatment readiness required.
May cause serious infections including tuberculosis, fungal, bacterial, and viral infections.
Drug-induced liver injury has been reported; monitor liver enzymes and bilirubin closely.
Avoid administration in patients with active tuberculosis or untreated infections.
Increased risk of infections following live vaccinations; live vaccines contraindicated during therapy.
Potential risk to fetus; use effective contraception during treatment and report pregnancies.
Serious allergic reactions may manifest as swelling, difficulty breathing, and hypotension.
Withhold therapy if serious infections or significant liver toxicity are identified.
Immunosuppressive effects may increase risk of malignancies with long-term use (theoretical).
Patients with a history of hepatic or immune disorders require individualized risk-benefit assessment.
Delayed hypersensitivity reactions have been observed; monitor for new or worsening symptoms.
Serious infusion-related reactions may necessitate discontinuation of infusion.
Risk of adverse effects can be potentiated by concomitant medications affecting immune system.
Do not use in patients with known hypersensitivity to mirikizumab or formulation excipients.
Post-marketing surveillance for long-term safety is ongoing; report adverse events promptly.

Contraindication

Known hypersensitivity to mirikizumab-mrkz or any excipients in the Omvoh formulation.
Active serious infections including tuberculosis, sepsis, or opportunistic infections.
History of life-threatening hypersensitivity or anaphylaxis to this drug or related biologics.
Patients who are not adequately screened or treated for latent or active tuberculosis.
Concurrent administration of live vaccines during treatment period.
Severe liver impairment with uncontrolled hepatic disease at time of initiation.
Known immune deficiency states unrelated to inflammatory bowel disease may preclude use.
Use in pediatric patients is contraindicated due to lack of safety and efficacy data.
Patients with history of severe infusion-related reactions to monoclonal antibodies.
Pregnant women unless potential benefit justifies potential risk; contraindicated unless clinically justified.
Any condition or circumstance where immunosuppression would pose unacceptable risk.
Previous treatment failure due to hypersensitivity to all available IL-23 inhibitors.
Uncontrolled concomitant autoimmune diseases requiring conflicting immunomodulatory therapy.
Known hypersensitivity to components such as polysorbate 80 or citrate buffer.
Inability or unwillingness to comply with monitoring and safety procedures during treatment.

Drug Interactions

No formal drug-drug interaction studies have been conducted with Omvoh to date.
Concomitant use of other immunosuppressive agents may increase risk of infections.
Potential additive immunosuppression when combined with corticosteroids or biologics.
Live vaccines should not be administered during or shortly after Omvoh treatment due to infection risk.
No significant metabolic interactions expected owing to proteolytic clearance pathway.
Concurrent use with other monoclonal antibodies requires careful clinical consideration.
No known effect on cytochrome P450 enzymes or transporter proteins reported.
Interactions with over-the-counter supplements and herbal products have not been systematically studied.
Patients should inform healthcare providers of all medications including vitamins and herbal products.
Avoid initiating other immunomodulators without professional medical advice during Omvoh therapy.
Potential interference with vaccines efficacy due to immunomodulatory effects.
May alter immune response to subsequent vaccinations; timing of immunizations must be planned.
Limited data on combination with JAK inhibitors or TNF inhibitors; caution advised.
No known pharmacokinetic interactions altering mirikizumab bioavailability or clearance.
Healthcare providers should monitor for new or worsening infections with concomitant immunosuppressants.

Preparations Of The Drug

Single-dose vial for intravenous infusion: 300 mg/15 mL (20 mg/mL concentration).
Single-dose prefilled pen for subcutaneous injection: 100 mg/mL solution.
Single-dose prefilled pen for subcutaneous injection: 200 mg/2 mL solution (100 mg/mL concentration).
Single-dose prefilled syringe for subcutaneous injection: 100 mg/mL solution.
Single-dose prefilled syringe for subcutaneous injection: 200 mg/2 mL solution (100 mg/mL concentration).
Formulations contain active ingredient mirikizumab-mrkz with excipients including anhydrous citric acid, polysorbate 80, sodium chloride, sodium citrate, and water for injection.
Not manufactured with natural rubber latex components to reduce allergy risk.
Prefilled pens and syringes designed for patient self-administration after training.
Parenteral preparations require refrigeration at 2°C to 8°C; protect from freezing and light.
Discard any preparations that have been frozen, exposed to light without packaging, or stored at room temperature exceeding 2 weeks.
Intravenous vials supplied for administration in clinical settings over 30 to 90 minutes depending on indication.
Prefilled injection devices intended for maintenance therapy via subcutaneous route.
Single-use, sterile preparations requiring appropriate disposal of sharps and biohazard waste.
Provided in packaging suitable to maintain stability and integrity during shipping and storage.
Manufactured by Eli Lilly and Company under stringent quality and regulatory standards.